Sign in or create an account to add this stock to your watchlist.
About Cepheid (NASDAQ:CPHD)
Cepheid is a molecular diagnostics company. The Company develops, manufactures and markets fully-integrated systems for testing in the Clinical and Non-Clinical markets. The Company's systems enable molecular testing for organisms and genetic-based diseases by automating otherwise complex manual laboratory procedures. The Company's systems integrate these steps and analyze biological samples in test cartridges. Its primary offering is the GeneXpert system, which integrates sample preparation in addition to Deoxyribonucleic acid (DNA) amplification and detection. The GeneXpert system is designed for a range of user types ranging from reference laboratories and hospital central laboratories to satellite testing locations, such as emergency departments and intensive care units within hospitals, as well as physician offices and other alternate site laboratories. It also offers the SmartCycler system, which integrates DNA amplification and detection to allow rapid analysis of a sample.
Industry, Sector and Symbol
Industry N/A
Sub-IndustryBiotechnology
SectorN/A
SymbolNASDAQ:CPHD
CUSIP15670R10
Phone+1-408-5414191
Debt
Debt-to-Equity Ratio0.76
Current Ratio4.30
Quick Ratio3.24
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A
Profitability
EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net Margins-6.88%
Return on Equity-11.54%
Return on Assets-5.18%
Miscellaneous
Employees1,700
Outstanding Shares72,890,000
Cepheid (NASDAQ:CPHD) Frequently Asked Questions
What is Cepheid's stock symbol?
Cepheid trades on the NASDAQ under the ticker symbol "CPHD."
How were Cepheid's earnings last quarter?
Cepheid (NASDAQ:CPHD) released its quarterly earnings data on Thursday, July, 28th. The scientific and technical instruments company reported $0.05 earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($0.14) by $0.19. The scientific and technical instruments company earned $146 million during the quarter, compared to analysts' expectations of $145.82 million. Cepheid had a negative net margin of 6.88% and a negative return on equity of 11.54%. The company's revenue for the quarter was up 10.2% on a year-over-year basis. During the same period in the previous year, the company earned ($0.06) EPS. View Cepheid's Earnings History.
Has Cepheid been receiving favorable news coverage?
Media coverage about CPHD stock has trended somewhat positive on Sunday, according to Accern. Accern identifies negative and positive press coverage by monitoring more than 20 million news and blog sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Cepheid earned a news sentiment score of 0.13 on Accern's scale. They also assigned news articles about the scientific and technical instruments company an impact score of 46.77 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company's share price in the next few days.
How do I buy shares of Cepheid?
Shares of CPHD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Cepheid's stock price today?
One share of CPHD stock can currently be purchased for approximately $52.95.
How can I contact Cepheid?
Cepheid's mailing address is 904 E Caribbean Dr, SUNNYVALE, CA 94089-1189, United States. The scientific and technical instruments company can be reached via phone at +1-408-5414191.
MarketBeat Community Rating for Cepheid (CPHD)
MarketBeat's community ratings are surveys of what our community members think about Cepheid and other stocks. Vote "Outperform" if you believe CPHD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CPHD will underperform the S&P 500 over the long term. You may vote once every thirty days.
Cepheid (NASDAQ:CPHD) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | N/A | N/A | N/A | N/A |
| Consensus Rating Score: | N/A | N/A | N/A | N/A |
| Ratings Breakdown: | 0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | N/A | N/A | N/A | N/A |
| Price Target Upside: | N/A | N/A | N/A | N/A |
Cepheid (NASDAQ:CPHD) Consensus Price Target History
Cepheid (NASDAQ:CPHD) Analyst Ratings History
Show:
(Data available from 5/27/2016 forward)
Cepheid (NASDAQ:CPHD) Earnings History and Estimates Chart
Cepheid (NASDAQ CPHD) Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 7/28/2016 | Q216 | ($0.1370) | $0.05 | $145.82 million | $146.00 million | View | Listen |  |
| 4/28/2016 | Q116 | $0.01 | $0.08 | $140.35 million | $144.80 million | View | N/A | |
| 2/2/2016 | Q415 | ($0.20) | ($0.14) | $146.95 million | $147.00 million | View | N/A | |
| 10/20/2015 | Q3 | ($0.31) | ($0.13) | $126.81 million | $126.50 million | View | Listen | |
| 7/23/2015 | Q215 | ($0.21) | ($0.06) | $130.70 million | $132.50 million | View | Listen | |
| 4/23/2015 | Q115 | ($0.17) | $0.06 | $125.50 million | $132.60 million | View | N/A | |
| 1/29/2015 | Q414 | ($0.13) | $0.11 | $125.34 million | $131.50 million | View | N/A | |
| 10/16/2014 | Q314 | ($0.16) | ($0.10) | $110.10 million | $115.20 million | View | Listen | |
| 7/17/2014 | Q214 | ($0.13) | ($0.10) | $115.47 million | $116.50 million | View | N/A | |
| 4/17/2014 | Q114 | ($0.19) | ($0.13) | $104.90 million | $106.90 million | View | N/A | |
| 1/30/2014 | Q413 | ($0.10) | ($0.07) | $102.17 million | $113.30 million | View | N/A | |
| 10/17/2013 | Q3 2013 | ($0.11) | ($0.02) | $93.81 million | $100.08 million | View | N/A | |
| 7/18/2013 | Q2 2013 | $0.04 | $0.02 | $92.57 million | $96.00 million | View | N/A | |
| 4/18/2013 | Q1 2013 | $0.10 | $0.11 | $89.12 million | $91.90 million | View | N/A | |
| 1/24/2013 | Q4 2012 | $0.11 | $0.20 | $92.87 million | $92.40 million | View | N/A | |
| 10/18/2012 | | ($0.07) | ($0.32) | | | View | N/A | |
| 7/19/2012 | | $0.11 | $0.11 | | | View | N/A | |
| 4/19/2012 | | ($0.01) | ($0.08) | | | View | N/A | |
| 1/26/2012 | | ($0.02) | ($0.03) | | | View | N/A | |
| 10/20/2011 | | $0.02 | $0.03 | | | View | N/A | |
| 7/21/2011 | | ($0.01) | $0.03 | | | View | N/A | |
| 4/20/2011 | | ($0.01) | $0.01 | | | View | N/A | |
| 1/27/2011 | | ($0.02) | $0.02 | | | View | N/A | |
| 10/21/2010 | Q3 2010 | ($0.06) | ($0.02) | | | View | N/A | |
| 7/22/2010 | Q2 2010 | ($0.10) | ($0.03) | | | View | N/A | |
| 4/22/2010 | Q1 2010 | ($0.10) | ($0.07) | | | View | N/A | |
| 1/28/2010 | Q4 2009 | ($0.12) | ($0.06) | | | View | N/A | |
| 10/28/2009 | Q3 2009 | ($0.12) | ($0.07) | | | View | N/A | |
| 7/30/2009 | Q2 2009 | ($0.12) | ($0.12) | | | View | N/A | |
| 4/23/2009 | Q1 2009 | ($0.13) | ($0.13) | | | View | N/A | |
| 2/5/2009 | Q4 2008 | ($0.16) | ($0.10) | | | View | N/A | |
| 10/28/2008 | Q3 2008 | ($0.11) | ($0.11) | | | View | N/A | |
| 7/24/2008 | Q2 2008 | ($0.05) | ($0.13) | | | View | N/A | |
| 5/1/2008 | Q1 2008 | ($0.07) | ($0.03) | | | View | N/A | |
| 2/28/2008 | Q4 2007 | ($0.08) | ($0.09) | | | View | N/A | |
(Earnings results data provided by Zacks Investment Research)
Cepheid (NASDAQ:CPHD) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Cepheid (NASDAQ CPHD) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 4.16%
Institutional Ownership Percentage: 95.75%
Cepheid (NASDAQ CPHD) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 8/17/2016 | Scott A Campbell | VP | Sell | 287 | $36.16 | $10,377.92 | 10,376 | |
| 8/4/2016 | Scott A Campbell | VP | Sell | 746 | $36.71 | $27,385.66 | 10,721 | |
| 5/3/2016 | Scott A Campbell | VP | Sell | 2,058 | $27.90 | $57,418.20 | 13,761 | |
| 5/2/2016 | Peter V Farrell | EVP | Sell | 390 | $28.90 | $11,271.00 | 19,837 | |
| 4/28/2016 | Peter V Farrell | EVP | Sell | 390 | $36.30 | $14,157.00 | 20,462 | |
| 4/25/2016 | John L Bishop | CEO | Sell | 110,000 | $35.50 | $3,905,000.00 | 194,449 | |
| 3/10/2016 | Peter V Farrell | EVP | Sell | 393 | $33.01 | $12,972.93 | 21,560 | |
| 2/8/2016 | Warren C. Kocmond, Jr. | COO | Sell | 292 | $28.53 | $8,330.76 | 13,125 | |
| 2/1/2016 | Warren C. Kocmond, Jr. | COO | Sell | 351 | $28.44 | $9,982.44 | 13,125 | |
| 1/22/2016 | Warren C. Kocmond, Jr. | COO | Sell | 157 | $33.16 | $5,206.12 | 13,750 | |
| 12/10/2015 | Peter V. Farrell | EVP | Sell | 394 | $31.67 | $12,477.98 | 21,975 | |
| 11/20/2015 | Robert J Easton | Director | Sell | 3,206 | $36.02 | $115,480.12 | 9,524 | |
| 11/17/2015 | Robert J Easton | Director | Sell | 2,724 | $34.84 | $94,904.16 | 9,524 | |
| 11/12/2015 | Robert J Easton | Director | Sell | 2,556 | $35.01 | $89,485.56 | 9,524 | |
| 10/30/2015 | Peter V. Farrell | EVP | Sell | 1,560 | $33.89 | $52,868.40 | 23,238 | |
| 8/27/2015 | Peter V. Farrell | EVP | Sell | 1,577 | $48.67 | $76,752.59 | 25,738 | |
| 8/25/2015 | Cristina Kepner | Director | Buy | 10,000 | $47.78 | $477,800.00 | 256,230 | |
| 6/26/2015 | Warren C Kocmond Jr | COO | Sell | 9,375 | $61.52 | $576,750.00 | | |
| 4/29/2015 | Thomas L Gutshall | Director | Sell | 1,800 | $56.62 | $101,916.00 | | |
| 4/21/2015 | Joseph H Smith | EVP | Sell | 91,866 | $54.51 | $5,007,615.66 | | |
| 4/20/2015 | John L Bishop | CEO | Sell | 100,000 | $55.20 | $5,520,000.00 | | |
| 2/25/2015 | Hollings Renton | Director | Sell | 9,375 | $57.76 | $541,500.00 | | |
| 2/13/2015 | Dean O Morton | Director | Sell | 12,500 | $58.51 | $731,375.00 | | |
| 2/3/2015 | Thomas D Brown | Director | Sell | 12,500 | $56.29 | $703,625.00 | | |
| 1/30/2015 | Andrew Miller | CFO | Sell | 6,677 | $57.64 | $384,862.28 | | |
| 1/12/2015 | Andrew Miller | CFO | Sell | 11,719 | $56.65 | $663,881.35 | | |
| 1/12/2015 | David H Persing | EVP | Sell | 5,000 | $56.90 | $284,500.00 | | |
| 1/12/2015 | Warren C Kocmond Jr | COO | Sell | 4,688 | $57.00 | $267,216.00 | | |
| 1/5/2015 | Andrew Miller | CFO | Sell | 2,250 | $54.95 | $123,637.50 | | |
| 1/5/2015 | Kerry Flom | EVP | Sell | 8,694 | $54.21 | $471,301.74 | | |
| 11/19/2014 | Dean O Morton | Director | Sell | 11,849 | $52.96 | $627,523.04 | | |
| 11/7/2014 | Hollings Renton | Director | Sell | 9,375 | $51.07 | $478,781.25 | | |
| 10/31/2014 | Andrew Miller | CFO | Sell | 12,167 | $53.84 | $655,071.28 | | |
| 10/31/2014 | David H Persing | EVP | Sell | 20,000 | $53.34 | $1,066,800.00 | | |
| 10/31/2014 | Dean O Morton | Director | Sell | 7,500 | $52.64 | $394,800.00 | | |
| 10/29/2014 | Kerry Flom | EVP | Sell | 7,077 | $51.36 | $363,474.72 | | |
| 10/29/2014 | Thomas L Gutshall | Director | Sell | 12,500 | $51.63 | $645,375.00 | | |
| 10/28/2014 | David H Persing | EVP | Sell | 15,000 | $51.51 | $772,650.00 | | |
| 10/3/2014 | Kerry Flom | EVP | Sell | 1,271 | $44.52 | $56,584.92 | | |
| 8/7/2014 | Warren C Kocmond Jr | EVP | Sell | 324 | $38.69 | $12,535.56 | | |
| 7/14/2014 | Kerry Flom | EVP | Sell | 2,812 | $49.72 | $139,812.64 | | |
| 7/3/2014 | Kerry Flom | EVP | Sell | 1,282 | $48.97 | $62,779.54 | | |
| 5/29/2014 | Kerry Flom | EVP | Sell | 4,265 | $45.49 | $194,014.85 | | |
| 5/22/2014 | Warren C Kocmond Jr | EVP | Sell | 1,300 | $42.38 | $55,094.00 | | |
| 4/29/2014 | Kerry Flom | EVP | Sell | 2,660 | $42.38 | $112,730.80 | 989 | |
| 4/25/2014 | John Bishop | CEO | Sell | 107,651 | $43.93 | $4,729,108.43 | 41,105 | |
| 4/22/2014 | John Bishop | CEO | Sell | 42,349 | $46.11 | $1,952,712.39 | 39,850 | |
| 4/22/2014 | Robert Easton | Director | Sell | 12,500 | $45.59 | $569,875.00 | 80,138 | |
| 4/3/2014 | Kerry Flom | EVP | Sell | 1,621 | $51.55 | $83,562.55 | 20,000 | |
| 4/1/2014 | Andrew Miller | CFO | Sell | 4,688 | $52.78 | $247,432.64 | 4,584 | |
| 3/13/2014 | Andrew Miller | CFO | Sell | 17,265 | $55.55 | $959,070.75 | 4,584 | |
| 1/31/2014 | Andrew Miller | CFO | Sell | 63,375 | $53.10 | $3,365,212.50 | 4,584 | |
| 1/31/2014 | John Bishop | CEO | Sell | 150,000 | $50.67 | $7,600,500.00 | 39,176 | |
| 1/31/2014 | Joseph Smith | EVP | Sell | 50,000 | $51.15 | $2,557,500.00 | 11,181 | |
| 1/3/2014 | Kerry Flom | EVP | Sell | 6,357 | $45.66 | $290,260.62 | 20,000 | |
| 1/2/2014 | Andrew Miller | CFO | Sell | 2,437 | $45.92 | $111,907.04 | 2,683 | |
| 12/23/2013 | Kerry Flom | EVP | Sell | 10,000 | $46.51 | $465,100.00 | 20,000 | |
| 10/30/2013 | David H Persing | VP | Sell | 5,000 | $41.35 | $206,750.00 | | |
| 10/29/2013 | Kerry Flom | EVP | Sell | 2,660 | $40.50 | $107,730.00 | | |
| 10/24/2013 | Thomas L Gutshall | Director | Sell | 3,000 | $40.07 | $120,210.00 | | |
| 10/18/2013 | David H Persing | VP | Sell | 20,000 | $40.59 | $811,800.00 | | |
| 9/24/2013 | Thomas Gutshall | Director | Sell | 3,000 | $38.97 | $116,910.00 | 90,175 | |
| 9/18/2013 | David Persing | VP | Sell | 5,000 | $39.34 | $196,700.00 | 177 | |
| 9/16/2013 | David Persing | VP | Sell | 5,000 | $38.95 | $194,750.00 | 177 | |
| 9/6/2013 | David H Persing | VP | Sell | 20,000 | $37.99 | $759,800.00 | | |
| 8/30/2013 | David Persing | VP | Sell | 5,129 | $36.62 | $187,823.98 | 177 | |
| 8/26/2013 | Thomas Gutshall | Director | Sell | 3,000 | $36.38 | $109,140.00 | 90,175 | |
| 8/21/2013 | Robert Easton | Director | Sell | 7,500 | $35.01 | $262,575.00 | 79,124 | |
| 7/24/2013 | Thomas L Gutshall | Director | Sell | 3,000 | $34.18 | $102,540.00 | | |
| 6/24/2013 | Thomas L Gutshall | Director | Sell | 3,000 | $32.91 | $98,730.00 | | |
| 5/28/2013 | Andrew Miller | CFO | Sell | 22,468 | $38.51 | $865,242.68 | | |
| 5/24/2013 | Thomas L Gutshall | Director | Sell | 3,000 | $37.90 | $113,700.00 | | |
| 5/13/2013 | Kerry Flom | EVP | Sell | 6,832 | $39.76 | $271,640.32 | | |
| 3/25/2013 | Thomas L Gutshall | Director | Sell | 3,000 | $38.28 | $114,840.00 | | |
| 2/4/2013 | Joseph H Smith | EVP | Sell | 38,400 | $36.20 | $1,390,080.00 | | |
| 12/24/2012 | Thomas L Gutshall | Director | Sell | 3,000 | $33.06 | $99,180.00 | | |
| 11/26/2012 | Thomas L Gutshall | Director | Sell | 7,778 | $31.94 | $248,429.32 | | |
(Data available from 1/1/2013 forward)
Cepheid (NASDAQ CPHD) News Headlines
| Source: |
|
| Date | Headline |
|---|
 | Cepheid expands respiratory disease portfolio with Xpert Xpress Strep A
seekingalpha.com - October 5 at 11:03 AM |
 | Head to Head Contrast: Cepheid (CPHD) vs. Varex Imaging (VREX)
www.americanbankingnews.com - September 9 at 4:06 AM |
| Contrasting Cepheid (CPHD) and HTG Molecular Diagnostics (HTGM)
www.americanbankingnews.com - August 5 at 7:06 AM |
| Financial Review: Sequenom (SQNM) & Cepheid (CPHD)
www.americanbankingnews.com - August 1 at 8:30 PM |
| Contrasting Cepheid (NASDAQ:CPHD) and Myriad Genetics (MYGN)
www.americanbankingnews.com - July 30 at 7:27 AM |
| Comparing Myriad Genetics (MYGN) & Cepheid (NASDAQ:CPHD)
www.americanbankingnews.com - July 29 at 10:11 AM |
| Reviewing Cepheid (CPHD) & Vascular Solutions (VASC)
www.americanbankingnews.com - July 28 at 7:14 AM |
| Head-To-Head Comparison: Myriad Genetics (MYGN) vs. Cepheid (CPHD)
www.americanbankingnews.com - July 22 at 7:36 AM |
| Head to Head Survey: Cepheid (NASDAQ:CPHD) versus Myriad Genetics (MYGN)
www.americanbankingnews.com - July 21 at 8:04 AM |
| Analyzing Cepheid (CPHD) and Alphatec Holdings (ATEC)
www.americanbankingnews.com - July 20 at 9:42 AM |
| Comparing Myriad Genetics (MYGN) & Cepheid (CPHD)
www.americanbankingnews.com - July 14 at 8:36 AM |
| Head-To-Head Comparison: Alphatec Holdings (ATEC) vs. Cepheid (NASDAQ:CPHD)
www.americanbankingnews.com - July 12 at 8:16 AM |
 | These drug and medical device companies made the most payments to L.A. hospitals
www.bizjournals.com - March 3 at 9:29 PM |
 | Integrated Investment Consultants, LLC Buys Vanguard FTSE Emerging Markets, Mylan NV, Omega ...
www.nasdaq.com - January 19 at 10:48 PM |
| Danaher initiates 2017 outlook
seekingalpha.com - December 15 at 4:53 PM |
 | CEPHEID Files SEC form 8-K, Completion of Acquisition or Disposition of Assets, Triggering Events That Accelerate or
biz.yahoo.com - November 7 at 11:02 PM |
 | Danaher (DHR) Announces Completion of Cepheid (CPHD) Acquisition - StreetInsider.com
www.streetinsider.com - November 7 at 7:55 AM |
| CEPHEID Files SEC form 10-Q, Quarterly Report
biz.yahoo.com - November 3 at 9:56 PM |
| CEPHEID Files SEC form 8-K, Change in Directors or Principal Officers
biz.yahoo.com - October 28 at 9:11 PM |
| IWO, MSCC, AZPN, CPHD: Large Outflows Detected at ETF
www.nasdaq.com - October 25 at 9:37 PM |
| Cepheid Says Receives Regulatory Clearances In Proposed Acquisition By Danaher
www.nasdaq.com - October 24 at 4:16 PM |
| Cepheid (CPHD) Announces Final Regulatory Hurdles Cleared to Close Danaher (DHR) Merger
www.streetinsider.com - October 24 at 4:16 PM |
| Cepheid (CPHD) Announces Final Regulatory Hurdles Cleared to Close Danaher (DHR) Merger - StreetInsider.com
www.streetinsider.com - October 24 at 9:34 AM |
| CEPHEID Files SEC form 8-K, Other Events, Financial Statements and Exhibits
biz.yahoo.com - October 24 at 9:33 AM |
| iShares Russell 2000 Growth ETF Experiences Big Outflow
www.nasdaq.com - October 14 at 4:15 PM |
Cepheid (NASDAQ:CPHD) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Cepheid (NASDAQ:CPHD) Income Statement, Balance Sheet and Cash Flow Statement
Cepheid (NASDAQ CPHD) Stock Chart for Sunday, May, 27, 2018
Loading chart…
